Here’s their curt, dismissive take on Follica. No mention of proprietary device, wounding, announcement of going to market soon….
‘The company conducted a European based phase 1 clinical trial in 2010, and no results have been announced to date. It is currently being run as a virtual company with no reports of pending clinical trials.’
I look forward to not reading the investment risk section. Not my kind of Thursday night.
Again, you're reading into this way too much and jumping to conclusions. All their statements about other companies are neutral. The investment memorandum for Histogen that
@Xaser94 found and posted in the OP is dated in February '16 which means it was put together in the months prior to February. Follica has been notorious for a lack of communication not to mention
@hellouser couldn't get any information regarding them at the '15 Hair Congress and was met with a brick wall every time he inquired. Furthermore, Xaser94 was able to finally dig deep and get us some info on them which he posted in this thread
https://www.gourmetstylewellness.com/interact/threads/lots-of-new-info-on-follica.98226/ in March which was AFTER Histogen released their memo in February.
It surprises me that you're surprised a company looking for investors would highlight the failures of their competition.
Agreed, but they weren't even bad mouthing anyone.
Sure, but if you need to spend large $$$ every six months forever then even their "conservative" projections are too optimistic. If for example replicel costs twice as much but the results last for years then they are screwed. As an investor I would think twice and it's probably why they have n't been able to get the money for the FDA trials and why they are trialing in less expensive countries.
Personally, I could afford it for a few years whilst I waiting for something better.
As stated previously in this thread you need multiple injections to target the right growth stages of all the follicles on your head - they are not synchronized. Their clinical trials have shown that there is still an increase in hair after
one injection a year past baseline. If you don't want to spend the money I can understand that but don't assume their "projections are too optimistic".
Every investor should always think twice and all these companies have been trialing in countries outside the US because the FDA is a dinosaur and doesn't have the proper regulations in place for this new wave of regenerative medicine.
You also state "trialing in less expensive countries"... Let's suppose your
assumption is right and it is cheaper in other countries. Business 101 would say its a no-brainer to trial your product for less in a country that will possibly let you bring it to market sooner and make money faster. Why wouldn't you pursue that? Especially as a start-up company.
I'll get both Histogened multiple times and then RepliSeidoed if that's what it takes.
I'm right there with you man lol desperate times call for desperate measures.
Well the main risk with histogen is that they are basically injecting growth factors (no cells) that could encourage cancerous as well as hair growth (same issues with WNT agonists) where as Replicel is basically inkeced cultured DP cells that they hope will migrate back to the follicles. From a safety profile Replicel is probably safer but a more difficult process to industrialise.
Histogen has stated multiple times that they are not injecting cells in an effort to specifically avoid any cancerous side effects, that they have an excellent safety profile, and have performed additional testing in regards to cancer monitoring. The Phase III testing in Mexico will include a class of 330 patients. This is a large trial which will give us further details on efficacy and safety.
I'm not trying to promote any of these companies, all I'm trying to do is present the information that already has been given to us and not make assumptions - take the information how you want.